Which company is the manufacturer of Mobotinib? How much does it cost?

Mobotinib, also known as mobosetinib orExkivity, is an important targeted therapy drug, mainly used to treat patients with non-small cell lung cancer carrying EGFR exon 20 insertion mutations. So, which company makes this high-profile drug? What's the price?

The manufacturer of Mobotinib is Takeda Pharmaceutical Co., Ltd. of Japan. As a leading global pharmaceutical company, Takeda Pharmaceuticals has been committed to the research and development, production and sales of innovative drugs aimed at improving the quality of life of patients. As one of Takeda Pharmaceutical's outstanding products, Mobotinib has received widespread attention and recognition for its significant clinical efficacy and good safety since its launch, bringing new treatment hope to patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

As for the price of mobotinib, it varies depending on its version and sales channel. At present, the price of the original drug Mobotinib is relatively high, and the price of each box may reach tens of thousands of yuan. This is mainly because original drugs require a large investment in research and development costs and are affected by factors such as intellectual property protection. However, for patients with limited financial conditions, the high price of original drugs may become a considerable burden.

Thankfully, in addition to the original drugs, there are also affordable generic versions on the market. For example, the generic version of Mobotinib produced by Lucius Pharmaceuticals in Laos has a specification of 40mg*120 tablets and sells for about more than 3,000 yuan. This price is relatively affordable, providing more patients with the possibility of treatment and greatly reducing their financial burden.

It should be noted that although the price of generic drugs is more advantageous, patients must choose formal channels when purchasing to ensure that the source and quality of the drugs are reliable. Medicines purchased through formal channels not only have guaranteed quality, but also enjoy corresponding after-sales services.

In short, the manufacturer of Mobotinib is Takeda Pharmaceutical Co., Ltd. of Japan, and its price varies depending on the version and sales channel. For patients who need treatment, choosing formal channels to purchase a drug version that suits them is the key to ensuring treatment effectiveness and drug safety.

References:

https://www.drugs.com/newdrugs/fda-approves-exkivity-mobocertinib-egfr-exon20-insertion-non-small-cell-lung-cancer-nsclc-5656.html

xa0